Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation
Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This non-inferiority study aims at comparing Versa® to the reference enoxaparin (Clexane®,
Sanofi-Aventis) in patients with high-risk unstable angina and NSTEMI. The main justification
is the search for scientific evidence to prove the Versa® effectiveness for this new
therapeutic indication, since it is a product with potential for reducing costs, with
effectiveness and safety comparable to the reference drug.